LINC01239

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, LINC01239 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated LINC01239 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher LINC01239 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LINC01239 expression acts as an unfavorable survival marker.

STAD are the cancer types where LINC01239 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
STADOSMedianII,III,IV0.1830.677.00424view →
Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

LINC01239–STAD (OS)

Kaplan–Meier survival curve for LINC01239 mutant vs wild-type samples in STAD.

Open the STAD breakdown →

Exploration